Showing 94 of 94on this page. Filters & sort apply to loaded results; URL updates for sharing.94 of 94 on this page
Biogen Email Format | biogen.com Email Addresses
New MS drug from Biogen and Alkermes wins approval - The Boston Globe
Biogen receives FDA approval for breakthrough ALS treatment: 'Pivotal ...
Privacy Center | Biogen
Biogen Headquarters And Global Offices
Biogen to Acquire Apellis in $5.6 Billion Deal - Pharma Journalist
Biogen opens a branch in Estonia: Europe has lots to learn from Estonia ...
Alzheimer’s Disease Latest Drug Treatment: Biogen Investors - Bloomberg
Biogen Surges as New Alzheimer's and Rare-Disease Drugs Drive Profit ...
Former J&J executive emerges as front-runner for Biogen top job - STAT ...
Biogen (BIIB) Lowers 2023 Earnings Guidance on Costs of Reata Purchase ...
Biogen to cut 1,000 jobs as focus turns to Alzheimer's drug Leqembi ...
Biogen shakes up R&D role, splitting it into two
Lawsuit Alleging $23 Million Contract Breach Against Biogen Moves ...
Biogen is buying up an immune drug developer for $1.8 billion
Biogen gets FDA approval for higher dose of genetic disorder drug | Reuters
Biogen settles 401(k) lawsuit for $9.75 million | Pensions & Investments
Biogen Logo
Biogen gets DOJ subpoena on business operations in foreign countries ...
Student Programs | Biogen
About Us - Biogen
Careers | Biogen
Code of Business Conduct | Biogen
FDA Approves New Alzheimer's Drug But Creators Biogen And Eisai Stock ...
Biogen (BIIB) $18 Billion Plunge May Have Hurt These Hedge Funds ...
Biogen Announces New Global Headquarters at Kendall Common, Cambridge
2024 Corporate Responsibility Report | Biogen
Biogen owes Genentech $88 million in MS drug dispute, US judge says ...
Biotech layoffs 2023: More layoffs hit Biogen as company cuts from ...
Biogen Locations In Us – Biogen Intranet – MUVZMJ
Biogen Beefs Up Immuno Pipeline with Potential $1.8B HI-Bio Acquisition ...
After Apellis deal, Biogen looks to fill early-stage pipeline
Biogen raises 2024 financial guidance as Leqembi sales pick up - Boston ...
1st Circ. OKs Class Action Claim Against Biogen Over Statement ...
Biogen Reaches Research Deal With Dayra in Immunology Push - Bloomberg
Biogen grows immunology and rare disease portfolio with Apellis buyout ...
Biogen Sells Its Biosimilar Stake in Samsung Bioepis, Reaps Handsome ...
Working at Biogen | Glassdoor
Έγκριση ΕΕ για υψηλή δόση nusinersen στη SMA από τη Biogen - Healthweb.gr
Biogen to acquire immunology biotech Apellis for $5.6 billion
Team - Biogen
Logo | Biogen
Life at Biogen
William Blair Issues Negative Forecast for Biogen Earnings
Biogen Official: TikTok, Instagram, X, Facebook, Twitter | Linktree
Biogen Automates Purchasing with Compleat
Environment | Biogen
Company | Biogen
Biogen | The Org
Biogen Soars as Alzheimer’s Approval Cheers Investors
Biogen jumps 43% in anticipation of possible Alzheimer's drug approval ...
Innover au service du collectif, c’est une mission chez Biogen - L ...
Biogen | DCL
Biogen Buys Apellis for $5.6 Billion to Expand Kidney Drugs - Bloomberg
Ökad vinst för Biogen
Biogen will seek approval of Alzheimer's drug
BIOGEN - Breaking BIOGEN News, Analysis, Photos and Videos | The Hill
Biogen Jobs and Company Culture
Biogen ALS Drug Wins US Approval to Treat Rare Form of Disease - Bloomberg
Biogen trims pipeline programs to cut costs, focus on Alzheimer's drug ...
In dramatic turn, Biogen seeks FDA approval for experimental Alzheimer ...
Sobre a Biogen
Five Questions Around Biogen in Wake of the New Alzheimer’s Drug Data ...
The Biogen Logo History, Colors, Font, And Meaning
Biogen wins FDA approval on new multiple sclerosis drug - The Boston Globe
Biogen Agrees to Pay $900 Million to Resolve Kickback Claims (BIIB ...
Biogen acquires Apellis Pharmaceuticals for $5.6 billion - Boston ...
Healthcare Professionals
Home [www.biogen.ca]
Kontakt
Health - Axios
Biogen, with $5.6B Apellis buy, builds out immunology offerings ...
Biogen’s Profit Forecast Tops Estimates on Cost-Cutting - Bloomberg
Biogen, Arsenal, Sangano, GSK, Pfizer: Readout Newsletter
U.S. health regulator extends review of Biogen's ALS drug | Reuters
Biogen-UCB's lupus drug meets main goal of late-stage trial | Reuters
Biogen’s Singhal Offers A Look Into Company's Pipeline Review
Verge Genomics’ Alice Zhang on a young biotech founder’s ‘superpower ...
Lupus Reveal Gives Investors a Peek at Biogen’s ‘Underappreciated ...
Contact us
Business
Biogen, BMC1 & BMC2, Luterbach, Switzerland - Dussman STS Group
Human Resources Manager - Activ
Best Workplaces in Belgium 2026 | Great Place To Work - English
Biogen's results beat estimates on strength in rare disease drugs | Reuters
Biogen’s ALS Drug Tofersen Gets Partial Backing From FDA Panel - Bloomberg
What’s Up With Biogen? - Barron's
Biogen's New Alzheimer's Drug: What You Need to Know Now - Memory ...
Motor Neurone Disease: investigational drug granted accelerated ...
Contact Us